Page last updated: 2024-10-21

xanthine and Liver Neoplasms

xanthine has been researched along with Liver Neoplasms in 6 studies

7H-xanthine : An oxopurine in which the purine ring is substituted by oxo groups at positions 2 and 6 and N-7 is protonated.
9H-xanthine : An oxopurine in which the purine ring is substituted by oxo groups at positions 2 and 6 and N-9 is protonated.

Liver Neoplasms: Tumors or cancer of the LIVER.

Research

Studies (6)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (16.67)	18.7374
1990's	3 (50.00)	18.2507
2000's	1 (16.67)	29.6817
2010's	1 (16.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Fitian, AI	1
Nelson, DR	1
Liu, C	1
Xu, Y	1
Ararat, M	1
Cabrera, R	1
WU, C	1
BAUER, JM	1
Ren, Y	1
Smith, A	1
Usami, M	1
Furuchi, K	1
Kasahara, H	1
Haji, S	1
Kitani, G	1
Iso, A	1
Sun, K	1
Sou, E	1
Zheng, JH	1
Sakata, K	1
Yamamoto, T	2
Moriwaki, Y	2
Agbedana, OE	1
Takahashi, S	2
Nasako, Y	1
Yokoyama, Y	1
Higashino, K	1
Cheng, J	1
Tsutsumi, Z	1
Ka, T	1
Hada, T	1

Clinical Trials (1)

Trial Overview

Trial			Phase	Enrollment	Study Type	Start Date	Status
A Phase 1, Open-label, Randomized, Two-period, Two-treatment, Crossover Study to Evaluate the Effects of Food on the Pharmacokinetics of Urate After a Single Dose of Inosine in Healthy Male Subjects[NCT02614469]			Phase 1	18 participants (Actual)	Interventional	2015-03-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

AUC (0-inf): Area Under the Serum Concentration-time Curve From Time 0 to Infinity

(NCT02614469)
Timeframe: -12 to 0 hr pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48 hrs post-dose

Intervention	mg*hr/dL (Mean)
Inosine Fed	2040
Inosine Fasted	2031

AUC (0-t): Area Under the Serum Concentration-time Curve From Time 0 to Time t (Time of Last Quantifiable Plasma Concentration)

(NCT02614469)
Timeframe: -12 to 0 hr pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48 hrs post-dose

Intervention	mg*hr/dL (Mean)
Inosine Fed	267
Inosine Fasted	268

Baseline Corrected AUC (0-inf): Baseline Corrected Area Under the Serum Concentration-time Curve From Time 0 to Infinity

Correction for individual endogenous urate levels was done by subtracting the individual mean endogenous baseline concentration prior to dosing from each post-dose concentration in the profile. The two samples collected at -12 h and 0 h (pre-dose) before the meal were used to measure the mean endogenous baseline concentrations in each dosing period (periods 1 and 2). (NCT02614469)
Timeframe: -12 to 0 hr pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, and 48 hrs post-dose

Intervention	mg*hr/dL (Mean)
Inosine Fed	80.4
Inosine Fasted	83.0

Baseline Corrected AUC (0-t): Baseline Corrected Area Under the Serum Concentration-time Curve From Time 0 to Time t (Time of Last Quantifiable Serum Concentration)

Correction for individual endogenous urate levels was done by subtracting the individual mean endogenous baseline concentration prior to dosing from each post-dose concentration in the profile. The two samples collected at -12 h and 0 h (pre-dose) before the meal were used to measure the mean endogenous baseline concentrations in each dosing period (periods 1 and 2). Negative concentrations were set to zero. (NCT02614469)
Timeframe: -12 to 0 hr pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48 hrs post-dose

Intervention	mg*hr/dL (Mean)
Inosine Fed	36.1
Inosine Fasted	39.3

Baseline Corrected Cmax: Baseline Corrected Maximum Serum Concentration

Correction for individual endogenous urate levels was done by subtracting the individual mean endogenous baseline concentration prior to dosing from each post-dose concentration in the profile. The two samples collected at -12 h and 0 h (pre-dose) before the meal were used to measure the mean endogenous baseline concentrations in each dosing period (periods 1 and 2). Negative concentrations were set to zero. (NCT02614469)
Timeframe: -12 to 0 hr pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48 hrs post-dose

Intervention	mg/dL (Mean)
Inosine Fed	1.73
Inosine Fasted	1.65

Baseline Corrected T1/2: Baseline Corrected Apparent Terminal Half-life

Intervention	hr (Mean)
Inosine Fed	44.3
Inosine Fasted	44.7

Baseline Corrected Tmax: Baseline Corrected Time of Maximum Serum Concentration

Correction for individual endogenous urate levels was done by subtracting the individual mean endogenous baseline concentration prior to dosing from each post-dose concentration in the profile. The two samples collected at -12 h and 0 h (pre-dose) before the meal were used to measure the mean endogenous baseline concentrations in each dosing period (periods 1 and 2). (NCT02614469)
Timeframe: -12 to 0 h pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, and 48 hrs post-dose

Intervention	hr (Median)
Inosine Fed	3.0
Inosine Fasted	3.0

Cmax: Maximum Observed Serum Urate Concentration

(NCT02614469)
Timeframe: -12 to 0 hrs pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hrs post-dose

Intervention	mg/dL (Mean)
Inosine Fed	6.6
Inosine Fasted	6.4

Safety Assessment (Vital Signs)

Number of participants with clinically significant findings in vital signs by investigator after study drug administration. (NCT02614469)
Timeframe: Up to 10 days after first study drug administration at Day 1 of Period 1

Intervention	participants (Number)
Inosine Fed	0
Inosine Fasted	0

Safety Assessment: Adverse Events

Number of participants with adverse events after study drug administration (NCT02614469)
Timeframe: Up to 10 days after first study drug administration at Day 1 of Period 1

Intervention	participants (Number)
Inosine Fed	0
Inosine Fasted	0

T1/2: Apparent Terminal Half-life

(NCT02614469)
Timeframe: -12 to 0 pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48 hrs post-dose

Intervention	hr (Mean)
Inosine Fed	242
Inosine Fasted	241

Tmax: Time of Maximum Serum Concentration

(NCT02614469)
Timeframe: -12 to 0 hr pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48 hrs post-dose

Intervention	hr (Median)
Inosine Fed	3.0
Inosine Fasted	3.0

Other Studies

6 other studies available for xanthine and Liver Neoplasms

Article	Year
Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS-MS. Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34, Issue:9 Topics: 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; Amino Acids; Bile Acids and Salts; Carcinoma, Hepatocell	2014
Catabolism of xanthine and uracil in tumor-bearing rats. Cancer research, 1962, Volume: 22 Topics: Animals; Carcinoma 256, Walker; Carcinoma, Hepatocellular; Hydantoins; Liver Neoplasms; Neoplasms; N	1962
Mechanism of metallothionein gene regulation by heme-hemopexin. Roles of protein kinase C, reactive oxygen species, and cis-acting elements. The Journal of biological chemistry, 1995, Oct-13, Volume: 270, Issue:41 Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Base Sequence; Carcinoma, Hepatocellular; Ce	1995
The effect of partial hepatectomy on blood purine levels in rats and patients. Advances in experimental medicine and biology, 1994, Volume: 370 Topics: Adenosine Triphosphate; Animals; Chromatography, High Pressure Liquid; DNA; Hemangioma; Hepatectomy;	1994
Extracellular concentrations of oxypurines in xanthine oxidase-deficient hepatoma-derived cell line HuH-7. Advances in experimental medicine and biology, 1994, Volume: 370 Topics: 5'-Nucleotidase; Adenine Phosphoribosyltransferase; Adenosine Deaminase; Carcinoma, Hepatocellular;	1994
Effect of inosine on the plasma concentration of uridine and purine bases. Metabolism: clinical and experimental, 2002, Volume: 51, Issue:4 Topics: Adult; Carcinoma, Hepatocellular; Creatinine; Dose-Response Relationship, Drug; Humans; Hypoxanthine	2002